Zeposia 0.92 mg hard capsules
Sponsors
Antwerp University Hospital, Celgene International II S.a.r.l., Azienda Ospedaliera Universitaria Integrata Verona, Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
Conditions
Moderately to Severely Active Crohn's DiseaseMultiple sclerosisProgressive Multiple SclerosisRelapsing Multiple Sclerosis (relapsing-remittingrelapsing-progressive)
Phase 2
Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placebo-controlled randomized clinical trial (MACSiMiSE-BRAIN)
Active, not recruitingCTIS2023-503190-38-00
Start: 2023-11-23Target: 120Updated: 2025-11-07
A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety,
Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric
Participants with Moderately to Severely Active Crohn’s Disease with an Inadequate Response
to Conventional Therapy
CompletedCTIS2023-508777-91-00
Start: 2023-05-16End: 2024-09-13Target: 50Updated: 2024-10-07
PRObiotic Therapy Examining Combinatorial Therapeutics in Multiple Sclerosis - phase II, multicenter, randomised, open-label clinical trial.
WithdrawnCTIS2025-520955-10-00
Target: 210Updated: 2025-10-20